Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27568247 | 0.93 | FFAR3 (0.50) | — | |
| Acetic Acid SCHEMBL8785366 | 0.87 | FFAR3 (0.64) | — | |
| Acetic Acid SCHEMBL282406 | 0.87 | — | — | |
| Acetone SCHEMBL2311348 | 0.87 | — | — | |
| Acetic Acid SCHEMBL28343178 | 0.87 | FFAR3 (0.64) | — | |
| Acetic Acid SCHEMBL2706810 | 0.87 | FFAR3 (0.64) | — | |
| Acetic Acid SCHEMBL5035361 | 0.87 | — | — | |
| Acetic Acid SCHEMBL10843702 | 0.85 | — | — | |
| Acetic Acid SCHEMBL890387 | 0.83 | FFAR3 (0.58) | — | |
| Acetic Acid SCHEMBL8842862 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111246917-A | Pharmaceutical composition comprising remogliflozin and an antidiabetic drug | 格兰马克药品有限公司 | 2020-06-05 | — | — | CN | claimed |
| CN-1450999-A | Novel piperazine derivatives | PFIZER PROD INC (US) | 2003-10-22 | — | — | CN | claimed |
| CN-117355517-A | Macrocyclic glucagon-like peptide 1 receptor agonists | 伊莱利利公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-112867717-A | Compounds useful as kinase inhibitors and uses thereof | 浙江同源康医药股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-111246917-A | Pharmaceutical composition comprising remogliflozin and an antidiabetic drug | 格兰马克药品有限公司 | 2020-06-05 | — | — | CN | disclosed |
| CN-110753540-A | Oral pharmaceutical formulation of regagliflozin | 格兰马克药品有限公司 | 2020-02-04 | — | — | CN | disclosed |
| CN-109641000-A | Benzodiazepines for oral inhalation and nasal use | PAION英国有限公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-108129484-A | Heteroaromatic ring derivative | 郭守东 | 2018-06-08 | — | — | CN | disclosed |
| CN-108084193-A | A kind of BRD4 protein inhibitors | 郭守东 | 2018-05-29 | — | — | CN | disclosed |
| EP-2878601-B1 | AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA | RIKEN (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-9604988-B2 | Agent for treating or inhibiting recurrence of acute myeloid leukemia | RIKEN (JP) | 2017-03-28 | — | — | US | disclosed |
| EP-1255735-A2 | PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2002024695-A2 | OCTAHYDRO-INDOLIZINES AND QUINOLIZINES AND HEXAHYDRO-PYRROLIZINES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002008219-A2 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001056990-A2 | PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| US-5439954-A | Cosmetics for topical application to skin as sunscreen agents | THE PROCTER & GAMBLE COMPANY (US) | 1995-08-08 | — | — | US | disclosed |
| CN-1039250-A | The porous fragment that is used for the salvage biological polymer | BAYLOR COLLEGE MEDICINE (US) | 1990-01-31 | — | — | CN | disclosed |
| US-4395423-A | Polycyclic cyanoketones | STERLING DRUG INC. (US) | 1983-07-26 | — | — | US | disclosed |
| US-4310517-A | Tumor-resolving and histolytic medicaments and their use | TROPONWERKE GMBH & CO., KG (DE) | 1982-01-12 | — | — | US | disclosed |
| EP-0009801-A1 | Pharmaceutical compositions containing polycyclic cyanoketones | STERLING DRUG INC. (US) | 1980-04-16 | — | — | EP | disclosed |